Intellia Therapeutics (NASDAQ:NTLA) EVP James Basta Sells 10,397 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP James Basta sold 10,397 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. This trade represents a 9.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $10.13 on Thursday. The company’s 50-day moving average is $9.52 and its 200-day moving average is $12.68. The firm has a market capitalization of $1.17 billion, a PE ratio of -2.37 and a beta of 2.05. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. During the same quarter last year, the company posted ($1.34) earnings per share. Intellia Therapeutics’s quarterly revenue was up 51.6% on a year-over-year basis. As a group, analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Bank of America dropped their price objective on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Guggenheim lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Evercore ISI set a $8.00 price target on shares of Intellia Therapeutics and gave the company an “in-line” rating in a report on Tuesday, November 11th. HC Wainwright cut their price objective on shares of Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Finally, Chardan Capital decreased their target price on Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Eleven investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $18.43.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. CWM LLC raised its position in shares of Intellia Therapeutics by 4.7% in the third quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after buying an additional 856 shares in the last quarter. Federated Hermes Inc. increased its stake in Intellia Therapeutics by 39.7% during the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after acquiring an additional 927 shares during the period. Cyndeo Wealth Partners LLC raised its holdings in Intellia Therapeutics by 9.3% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after acquiring an additional 995 shares in the last quarter. Interchange Capital Partners LLC raised its holdings in Intellia Therapeutics by 9.7% in the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after acquiring an additional 1,030 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its position in shares of Intellia Therapeutics by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after acquiring an additional 1,126 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.